85336-83-0

Usage

Uses

Used in Chemical Synthesis:
2,2-BIS(4-METHOXYLPHENYL)ETHYLAMINE is used as an intermediate in the production of various organic compounds for its ability to facilitate the synthesis of dyes, pharmaceuticals, and polymers. Its chemical structure allows for versatile reactions that contribute to the formation of a range of end products.
Used in the Production of Resins and Adhesives:
In the chemical industry, 2,2-BIS(4-METHOXYLPHENYL)ETHYLAMINE is utilized as a crosslinking agent, playing a crucial role in the manufacturing process of resins and adhesives. Its inclusion enhances the properties of these materials, such as their durability and bonding strength.
Safety Considerations:
Given its potential health hazards, 2,2-BIS(4-METHOXYLPHENYL)ETHYLAMINE should be handled and used with caution. Adequate safety measures should be implemented to minimize risks associated with its use, ensuring the well-being of individuals involved in its production and application.

InChI:InChI=1/C16H19NO2/c1-18-14-7-3-12(4-8-14)16(11-17)13-5-9-15(19-2)10-6-13/h3-10,16H,11,17H2,1-2H3

Upstream product

• 36697-31-1 2,2-bis-(p-methoxyphenyl)-1-nitroethylene 
• 35582-69-5 bis-3,3-(p-methoxyphenyl)-propionic acid 
• 123-11-5 4-methoxy-benzaldehyde 
• 13139-86-1 4-methoxyphenyl magnesium bromide 
• 7525-23-7 4,4'-dimethoxydiphenylmethyl chloride 
• 728-87-0 4,4'-Dimethoxybenzhydrol 
• 4356-69-8 1,1-bis-(4-methoxyphenyl)ethylene 
• 100-66-3 methoxybenzene 
• 85078-27-9 4,4'-(2-nitroethane-1,1-diyl)bis(methoxybenzene) 

Downstream Products

• 102890-46-0 7-methoxy-4-(4-methoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline 
• 101442-06-2 7-methoxy-4-(4-methoxy-phenyl)-isoquinoline 

Relevant academic research and scientific papers

Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer

Focal adhesion kinase (FAK) is a tyrosine kinase that is overexpressed and activated in several advanced-stage solid cancers. In cancer cells, FAK promotes the progression and metastasis of tumours. In this study, we used structure-based virtual screening to filter a library of more than 210K compounds against the focal adhesion targeting FAK-focal adhesion targeting (FAT) domain to identify 25 virtual hit compounds which were screened in the invasive breast cancer line (MDA-MB-231). Most notably, compound I showed low micromolar antiproliferative activity, as well as antimigratory activity. Moreover, examination in a model of triple negative breast cancer (TNBC), revealed that, despite not effecting FAK phosphorylation, compound I significantly impairs proliferation whilst impairing focal adhesion growth and turnover leading to reduced migration. Further optimisation and synthesis of analogues of the lead compound I using a four-step synthetic procedure was performed, and analogues were assessed for their antiproliferative activity against three breast cancer (MDA-MB-231, T47D, BT474) cell lines and one pancreatic cancer (MIAPaCa2) cell line. Compound 5f was identified as a promising lead compound with IC50 values in the range of 4.59–5.28 μM in MDA-MB-231, T47D, BT474, and MIAPaCa2. Molecular modelling and pharmacokinetic studies provided more insight into the therapeutic features of this new series.